Abstract

Abstract – Submission Guidelines

SUBMIT ABSTRACT

1. General information

• The abstract must be prepared in English.
• The abstract should include key information organized in bullet points: Introduction, Objective, Material and methods, Results, and Conclusions. Commonly used abbreviations are allowed; other abbreviations should be explained. Drug names must be provided according to international nomenclature.
• Abstracts can only be submitted via online conference participant management system.
• To submit an abstract, you must first register online (REGISTER NOW).
• The final deadline for abstract submission is March 16, 2026, 23:59:59.
• Abstracts submitted after this deadline will not be accepted. Submissions sent by mail, fax, or e-mail will also not be accepted.
• Each submitted abstract will be anonymously reviewed by independent reviewers.
• The review process will be completed by April 10, 2026.
• Authors will be notified of acceptance or rejection by April 20, 2026.
• The organizer will contact only the first author.

SUBMIT ABSTRACT

2. Abstract topic categories

Authors must select one category that best fits the submitted abstract:

• Early diagnosis
• Semiology/ Clinical phenotyping 
• Neurodevelopment
• New and emerging  therapies
• Neurogenetics
• Imaging
• Quality of life
• Varia

3. Abstract structure

The abstract must include:

• Title (without abbreviations, in ALL CAPITAL LETTERS),
• Full names of all authors,
• Name of the institution and city,
• Text of the abstract, which should include a brief introduction and study objective, description of materials and methods, results obtained, and conclusions (maximum 2,500 characters including spaces and tables).
• Do not include figures, institution address (street, postal code), academic degrees or references.
• Listing research grants supporting the study is allowed (counts towards the final character limit).